The final payment amounts to approximately EUR 130,000, bringing the total amount received by the Company from the EIC Accelerator Fund to approximately EUR 2,380,000 to support the ongoing Phase I/IIa CARMA study with Elicera's CAR T-cell therapy ELC-301.

The CARMA study is a Phase I/IIa clinical trial evaluating the safety and preliminary efficacy of ELC-301 (a CD20-targeted CAR T-cell therapy armed with the iTANK platform) in patients with relapsed or refractory B-cell lymphoma. The grant from the EIC Accelerator Fund has been of great importance in financing the study in parallel with other funding sources.

This approval marks a successful conclusion of the formal reporting process to the European Commission/EIC and confirms that all reporting requirements have been fulfilled.

Relevance for Elicera

· The grant has strengthened the Company's financial position and enabled continued progress in the CARMA study, thereby delaying the need for additional capital.

· The approved final reporting strengthens Elicera's track record vis-à-vis both public funders and investors.

· The results from the CARMA study, which have shown promising clinical data so far, have been reported within the framework of the project.